FDA Moves To Implement New GMP Policies

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-02-2004
Volume 28
Issue 11

Phase II of FDA's GMP modernization plan may involve revising regulations to fit new policies and inspection and review programs.

External Link - article-132382.pdf

Articles in this issue
Still Waiting for Answers
Method Validation by Phase of Development: An Acceptable Analytical Practice
Comparing and Contrasting Barrier Isolator Decontamination Systems
November 2004
In the Spotlight-November 2004
Searching for a Viable Business Model
Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development
FDA Moves To Implement New GMP Policies
Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Benuvia Awarded NIH Contract for GMP Synthesis of Psilocybin, Other Drug Substances

Patrick Lavery
March 25th 2025
Article

The contract will support R&D of high-quality APIs for substance use disorders and mental health conditions, starting with synthesis and scale-up of psilocybin, which is derived from mushrooms.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy

Patrick Lavery
March 25th 2025
Article

Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Latigo Biotherapeutics Raises $150 Million to Advance Non-Opioid Pain Therapeutics

Feliza Mirasol
March 24th 2025
Article

With financing led by Blue Owl Capital, Latigo will use the funds to further develop non-opioid pain treatments as well as develop other candidates in its pipeline.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

Feliza Mirasol
March 18th 2025
Article

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.